Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations
Open Access
- 23 April 2019
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 9 (4) , 158
Abstract
The phosphatidylinositol 3-kinase (PI3K) pathway is involved in a myriad of cellular signalling pathways that regulate cell growth, metabolism, proliferation and survival. As a result, alterations in the PI3K pathway are frequently associated with human cancers. Indeed, PIK3CA—the gene encoding the p110α catalytic subunit of PI3K—is one of the most commonly mutated human oncogenes. PIK3CA mutations have also been implicated in non-malignant conditions including congenital overgrowth syndromes and vascular malformations. In order to study the role of PIK3CA mutations in driving tumorigenesis and tissue overgrowth and to test potential therapeutic interventions for these conditions, model systems are essential. In this review we discuss the various mouse models currently available for preclinical studies into the biological consequences and clinical significance of PIK3CA mutations.Keywords
This publication has 76 references indexed in Scilit:
- Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047ROncogenesis, 2013
- Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CANature Genetics, 2012
- De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromesNature Genetics, 2012
- Novel mutations target distinct subgroups of medulloblastomaNature, 2012
- Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES SyndromeThe American Journal of Human Genetics, 2012
- Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutationsOncogene, 2012
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanismsNature Medicine, 2011
- PI3 Kinase Signals BCR-Dependent Mature B Cell SurvivalCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Class I PI3K in oncogenic cellular transformationOncogene, 2008